BioCentury | Aug 22, 2020
Translation in Brief

IPD’s synthetic bio unlocks target combos for cell therapy; plus Merck’s oral STING agonist, Surrozen’s regenerative therapy and more

Synthetic switches aim T cells at cells expressing antigen combos David Baker’s team at University of Washington’s Institute for Protein Design published a study in Science showing its synthetic protein switches can direct T cells...
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

...Case Western Reserve University Distillery Therapeutics Sepsis Zinc and ring finger 1 (ZNRF1) Cell culture and mouse studies suggest inhibiting ZNRF1...
BioCentury | Jun 27, 2017
Distillery Therapeutics

Infectious disease

...INDICATION: Sepsis Cell culture and mouse studies suggest inhibiting ZNRF1 could help treat sepsis. In lipopolysaccharide...
...could help treat sepsis. In lipopolysaccharide (LPS)-treated human and mouse macrophage cell lines, knockdown of ZNRF1...
...the lung. Next steps could include identifying and testing ZNRF1 inhibitors in sepsis models. TARGET/MARKER/PATHWAY: Zinc and ring finger 1 (ZNRF1)...
BioCentury | Jun 25, 2015
Distillery Therapeutics

Therapeutics: Ring finger protein 43 (RNF43); zinc and ring finger 3 (ZNRF3)

Cancer INDICATION: Cancer Cell culture and mouse studies suggest WNT pathway inhibitors could help treat gastrointestinal, colonic and other cancers that harbor mutations in RNF43 and ZNRF3 . Organoids cultured from RNF43/ZNRF3 double-knockout mouse epithelial intestinal...
BioCentury | May 31, 2012
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Zinc and ring finger 3 (ZNRF3); ring finger protein 43 (RNF43) An in vitro study identified two new components of the wingless-type MMTV...
Items per page:
1 - 5 of 5